Five Prime Therapeutics, Inc. (FPRX) is a biomedical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on FPRX's earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Five Prime could be a solid choice for investors.Current Quarter Estimates for FPRX
In the past 30 days, 1 estimate has gone higher for Five Prime with no downward revision in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of 53 cents a share 30 days ago, to a loss of 37 cents today, a move of 30.2%.Current Year Estimates for FPRX
Meanwhile, Five Prime's current year figures are also looking quite promising, with 1 estimate moving higher in the past month, compared to no downward revision. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of $2.02 per share 30 days ago to a loss of $1.60 per share today, an increase of 20.8%.Bottom Line
The stock has also started to move higher lately, adding 22.3% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days
. Click to get this free report >>FIVEPRIME THERA (FPRX): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research